D. Boral Capital Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

D. Boral Capital reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report published on Friday,Benzinga reports. The firm currently has a $2.00 price target on the stock.

Separately, HC Wainwright boosted their target price on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 4th.

Lineage Cell Therapeutics Stock Up 14.6 %

Shares of NYSEAMERICAN:LCTX opened at $0.59 on Friday. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61. The company has a market cap of $130.07 million, a PE ratio of -4.92 and a beta of 1.16.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Defender Capital LLC. increased its stake in shares of Lineage Cell Therapeutics by 0.6% during the 3rd quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock worth $4,528,000 after purchasing an additional 29,223 shares in the last quarter. Raffles Associates LP grew its holdings in Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after buying an additional 150,000 shares during the last quarter. Geode Capital Management LLC increased its position in Lineage Cell Therapeutics by 2.3% during the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after buying an additional 83,274 shares in the last quarter. State Street Corp raised its holdings in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after acquiring an additional 45,483 shares during the last quarter. Finally, MAI Capital Management lifted its position in shares of Lineage Cell Therapeutics by 2.2% in the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock valued at $1,516,000 after acquiring an additional 35,907 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.